Ipsen Logo

Ipsen

Developing innovative medicines for Oncology, Rare Diseases, and Neuroscience.

IPN | PA

Overview

Corporate Details

ISIN(s):
FR0010259150 (+17 more)
LEI:
549300M6SGDPB4Z94P11
Country:
France
Address:
65 QUAI GEORGES GORSE, 92100 BOULOGNE-BILLANCOURT
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Ipsen is a global biopharmaceutical company focused on developing and commercializing innovative medicines in specialty care. The company concentrates its efforts on three key therapeutic areas: Oncology, Rare Diseases, and Neuroscience. Ipsen's strategy targets conditions with high unmet medical needs, leveraging its global infrastructure, scientific expertise, and strategic partnerships to accelerate its research pipeline and bring transformative treatments to patients worldwide. The company is committed to advancing science with the purpose of improving health outcomes for underserved patient populations.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-07 18:30
Transaction in Own Shares
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
English 84.4 KB
2025-10-07 18:30
Transaction in Own Shares
IPSEN - Buy-back programme - Art 5 of MAR - Week 40 - 2025
English 85.2 KB
2025-09-30 18:30
Transaction in Own Shares
IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2025
English 81.9 KB
2025-09-30 18:30
Transaction in Own Shares
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
English 81.3 KB
2025-09-16 18:30
Transaction in Own Shares
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
English 86.5 KB
2025-09-16 18:30
Transaction in Own Shares
IPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2025
English 86.4 KB
2025-09-02 18:00
Transaction in Own Shares
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
English 269.9 KB
2025-09-02 18:00
Transaction in Own Shares
IPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 2025
English 542.0 KB
2025-07-10 18:30
Declaration of Voting Results & Voting Rights Announcements
Ipsen - Juin 2025 - Information mensuelle relative au nombre total des droits d…
French 124.2 KB
2025-07-10 18:30
Declaration of Voting Results & Voting Rights Announcements
Ipsen - June 2025 - Monthly information relative to the total number of voting …
English 106.7 KB
2025-07-01 09:00
Environmental & Social Information
Gemeinsam fur eine bessere Zukunft: Ipsen Pharma GmbH engagiert sich am Communi…
German 8.6 KB
2025-06-17 18:00
Transaction in Own Shares
IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2025
English 271.6 KB
2025-06-17 18:00
Transaction in Own Shares
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
English 468.0 KB
2025-06-13 18:00
Transaction in Own Shares
IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2025
English 324.3 KB
2025-06-13 18:00
Transaction in Own Shares
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
English 293.1 KB

Automate Your Workflow. Get a real-time feed of all Ipsen filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ipsen

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ipsen via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-09-04 N/A Other Sell 850 91,374.66 EUR
2024-02-27 N/A Other Buy 500 51,916.20 EUR
2023-07-31 N/A Other Buy 50,048 N/A

Peer Companies

Halychpharm Logo
A pharmaceutical manufacturer of finished medicines and plant-derived phytochemical substances.
Ukraine
GFARM
HANALL BIOPHARMA CO.,LTD Logo
Develops innovative medicines for chronic diseases through antibody and small molecule research.
South Korea
009420
Hana Pharm. Co., Ltd. Logo
Pharmaceutical firm specializing in anesthetics and narcotic analgesics for global markets.
South Korea
293480
Hanmi Pharm. Co., Ltd. Logo
Biopharma firm developing innovative diabetes and cancer drugs for patients and professionals.
South Korea
128940
Hansa Biopharma Logo
Develops antibody-cleaving enzymes to treat rare diseases and enable organ transplants.
Sweden
HNSA
Harmony Biosciences Holdings, Inc. Logo
Develops innovative therapies for rare neurological diseases, focusing on conditions like narcolepsy.
United States of America
HRMY
HARROW, INC. Logo
Develops branded ophthalmic therapies and custom compounded solutions for North American eyecare.
United States of America
HROW
HCW Biologics Inc. Logo
Developing novel immunotherapies to treat aging-related chronic inflammation.
United States of America
HCWB
HEALIOS K.K. Logo
Develops iPS and somatic stem cell therapies for diseases like ARDS and cancer.
Japan
4593
Heartseed株式会社 Logo
Develops iPSC-derived cell therapies to regenerate heart tissue for heart failure.
Japan
219A

Talk to a Data Expert

Have a question? We'll get back to you promptly.